case_images: PMC11137779_01
case_images: Timeline of the patient.. At baseline, no targetable mutations, but liquid biopsy detected TP53, ARID1A, KEAP1 and SMARCA4 mutations. After complete response, at 14 months, a solitary pulmonary nodule was detected on CT, and it was PET avid indicative of potentially acquired resistance to PD-1 therapy. Liquid biopsy detected clearance and was inconsistent with radiology. Further investigation with tissue biopsy at 16 months revealed a benign diagnosis and refuted the progression of the disease.
case_images: IFSO_A_2340322_F0001_C.jpg
case_images: PMC11137779_01_IFSO_A_2340322_F0001_C.jpg
case_images: F0001
case_images: TP53, ARID1A, KEAP1, MAP2K and SMARCA4 (Figure 1). The patient initially received carboplatin, pemetrexed, and pembrolizumab and immediately achieved an excellent clinical and a complete radiological response. After four cycles of combination therapy, both carboplatin and pemetrexed were ceased and pembrolizumab was continued as maintenance therapy every 3 weeks. The deep response persisted for more than 14 months while on pembrolizumab alone, most consistent with an ongoing response to PD-1 blockade therapy.
case_images: PMC11137779_02